Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Share-based compensation expense

Asset impairment and restructuring costs

Expected credit losses on financial assets and related charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Canopy Growth

Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

New Canopy Growth CEO David Klein has a great track record, but has his work cut out for him to turn around the company and CGC stock.
The post New Canopy Growth CEO Needs to Hit the Ground Running appeared first on InvestorPlace.

New Canopy Growth CEO Needs to Hit the Ground Running

Aurora Cannabis

The presence of THCP may help explain why some strains have more of an effect on users than you'd expect based on their THC levels.

Researchers Discover Cannabis Compound That May Be 30 Times More Potent Than THC

Constellation Brands

The marijuana producer has been more anchor than sail for the alcoholic beverages distributor.

Did Constellation Brands Waste $4 Billion on Canopy Growth?

Aphria

Only one of these pot stocks is a strong buy right now.

Better Buy:  Canopy Growth vs.  Aphria

Some feel Canopy Growth’s delay launching cannabis-infused drinks is bad for CGC stock. Here’s why that’s not the case.

Don’t Judge CGC Stock on the Beverage Release Miss Alone

That rate is significantly higher than key segments of the nation's economy.

Canadian Cannabis GDP Contribution Rises by 15% in November

Do analysts really think beaten-down Aurora can top Canopy Growth in performance this year? Yep.

Why Wall Street Is Surprisingly More Bullish About Aurora Cannabis Than Canopy Growth

Doug Ford blames cannabis producers for the slow initial rollout of marijuana retail stores.

Ontario Premier Says Province Will Lead Canada in Number of Pot Dispensaries

CGC stock announced its delayed the launch of its cannabis-infused beverage line. Here is what this means for the company going forward.

The Infused Beverage Miss Is Symptomatic of the Trouble With CGC Stock

Note to investors: You can probably ignore this upgrade.

Wall Street's Upgrade of This Popular Pot Stock Overlooks Serious Flaws

The cannabis market has absorbed serious pain in 2019, creating a credibility problem for individual names like CGC stock. However, underappreciated catalysts may make this a surprising hit in 2020.

3 Reasons Why Contrarianism Might Finally Work for CGC Stock

Investors may not offer CGC stock a Constellation premium much longer, which means shares could head much lower.
The post Sell Canopy Growth Shares Now Before CGC Loses Its Spark appeared first on InvestorPlace.

Sell Canopy Growth Shares Now Before CGC Loses Its Spark

The big marijuana stock also gets a hefty price target raise.

Influential Canadian Bank Upgrades Canopy Growth Recommendation to Buy; Shares Rise 11%

Local banker throws its support behind Canadian cannabis play.

Why Canopy Growth Stock Popped 11% Today

Twenty-First Century Fox

Alphabet

Intuit

CarMax

Twitter

DENTSPLY SIRONA

One of the biggest stories on Wall Street in 2020 will be the U.S. presidential election in November.

8 Stocks To Buy For This 2020 Presidential Election Year

It has been a rough time for the companies that stand to benefit from the waves of cannabis legalization efforts.

Why Canopy Growth Shares Could Rally 40% More in 2020

Cronos Group

Tilray Brands

Cannabis stocks had a huge showing on Wall Street last year. In fact, most of the news flow surrounding these stocks had investors pouring money into them.

Cannabis Short Interest Keeps Getting Higher and Higher

Aggregate Canadian cannabis sales since October 2018 are nearing $1 billion.

Canada's Marijuana Sales Top $100 Million in a Month for the First Time

The two companies have made changes at the top that could pay off.

1 Thing That Can Help Both Tilray and Canopy Growth Turn Things Around

The key investor takeaway is that Canopy Growth continues to have major flaws in its growth story.

Canopy Growth: Major 2.0 Flaws

Pot stocks are rising from the ashes, and Canopy Growth is leading the pack. That said, here are 3 reasons to be bullish on CGC stock.

3 Reasons to Have Optimism in Canopy Growth Stock

With Canopy Growth's Cannabis 2.0 miss, CGC stock looks unlikely to deliver a turnaround until at least the second half of the year.
The post Canopy Growth Turnaround Misses Important Milestone appeared first on InvestorPlace.

Canopy Growth Turnaround Misses Important Milestone

Surprisingly, these are two of the most popular marijuana stocks with investors.

The Only 2 Pot Stocks Wall Street Expects to Decline in Value

HEXO Corp

OrganiGram Holdings Inc.

SNDL Inc.

With Canadian pot sales expected to hit $5 billion annually by 2024, it pays to know the biggest names in the industry.

The 10 Largest Canadian Marijuana Stocks

Cannabis sold under license costs nearly twice as much as product from illegal sources.

News for Canopy Growth Stock (CGC)